PA8813901A1 - Paramixovirus oncolíticos atenuados que codifican citoquinas de aves - Google Patents

Paramixovirus oncolíticos atenuados que codifican citoquinas de aves

Info

Publication number
PA8813901A1
PA8813901A1 PA20098813901A PA8813901A PA8813901A1 PA 8813901 A1 PA8813901 A1 PA 8813901A1 PA 20098813901 A PA20098813901 A PA 20098813901A PA 8813901 A PA8813901 A PA 8813901A PA 8813901 A1 PA8813901 A1 PA 8813901A1
Authority
PA
Panama
Prior art keywords
virus
oncolitical
bird
codify
disease
Prior art date
Application number
PA20098813901A
Other languages
English (en)
Inventor
Rudolf Beier
Florian Puehler
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PA8813901A1 publication Critical patent/PA8813901A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN VIRUS A ARN ONCOLÍTICO RECOMBINANTE DE LA ENFERMEDAD DE NEWCASTLE PARA EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA, QUE COMPRENDE AL MENOS UN TRANSGEN QUE CODIFICA UNA CITOQUINA DE AVES, EN DONDE EL VIRUS A ARN ONCOLÍTICO RECOMBINANTE DE LA ENFERMEDAD DE NEWCASTLE SE PUEDE OBTENER A PARTIR DE UN VIRUS A ARN DE LA ENFERMEDAD DE NEWCASTLE ONCOLÍTICO VELOGÉNICO O MESOGÉNICO. LA EXPRESIÓN MEDIADA POR VIRUS DE LA CITOQUINA EN LAS CÉLULAS HUÉSPED NATURAL CONDUCE A UNA PATOGENICIDAD REDUCIDA DEL VIRUS PARA ESPECIES DE AVES. AÚN MÁS, EL GENOMA DEL VIRUS PUEDE CODIFICAR PROTEÍNAS DE UNIÓN, ENZIMAS CONVERTIDORAS DE PRODROGAS O/Y PROTEASAS. LA EXPRESIÓN SELECTIVA DE ESTAS MOLÉCULAS EN CÉLULA TUMORALES INFECTADAS CON VIRUS INCREMENTA EL EFECTO ANTIMURAL DEL VIRUS.
PA20098813901A 2008-01-29 2009-01-28 Paramixovirus oncolíticos atenuados que codifican citoquinas de aves PA8813901A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2433308P 2008-01-29 2008-01-29
EP08001643A EP2085092A1 (en) 2008-01-29 2008-01-29 Attenuated oncolytic paramyxoviruses encoding avian cytokines

Publications (1)

Publication Number Publication Date
PA8813901A1 true PA8813901A1 (es) 2009-08-26

Family

ID=39708421

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098813901A PA8813901A1 (es) 2008-01-29 2009-01-28 Paramixovirus oncolíticos atenuados que codifican citoquinas de aves

Country Status (22)

Country Link
US (1) US20100092430A1 (es)
EP (2) EP2085092A1 (es)
JP (1) JP2011510638A (es)
KR (1) KR20100113096A (es)
CN (1) CN102099045A (es)
AR (1) AR070272A1 (es)
AU (1) AU2009210301A1 (es)
BR (1) BRPI0906354A2 (es)
CA (1) CA2711571A1 (es)
CL (1) CL2009000190A1 (es)
CO (1) CO6290693A2 (es)
CR (1) CR11616A (es)
DO (1) DOP2010000233A (es)
EA (1) EA201001202A1 (es)
EC (1) ECSP10010375A (es)
IL (1) IL206382A0 (es)
MX (1) MX2010008370A (es)
PA (1) PA8813901A1 (es)
PE (1) PE20091355A1 (es)
TW (1) TW200936159A (es)
WO (1) WO2009095167A1 (es)
ZA (1) ZA201006151B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2529747T (pt) 2005-12-02 2018-05-09 Icahn School Med Mount Sinai Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
US9937196B2 (en) * 2009-06-19 2018-04-10 University Of Maryland, College Park Genomic sequence of avian paramyxovirus type 2 and uses thereof
BR112014000787B1 (pt) 2011-08-05 2021-04-13 Sillajen Biotherapeutics, Inc Método para produzir vírus vaccinia
GEP20196976B (en) * 2013-03-14 2019-06-10 Sloan Kettering Cancer Center Memorial Newcastle disease viruses and uses thereof
CA2922071C (en) * 2013-09-03 2022-05-03 Medimmune Limited Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia
EP3441084A1 (en) 2014-02-27 2019-02-13 Viralytics Limited Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
CN108362875A (zh) * 2018-01-10 2018-08-03 华南农业大学 一种鉴别新城疫感染与免疫的间接elisa方法
CN111094324B (zh) * 2018-03-14 2023-10-10 武汉博威德生物技术有限公司 一种溶瘤病毒、合成dna序列及其应用
TW202043466A (zh) * 2019-01-25 2020-12-01 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1394259A3 (en) 1994-07-18 2004-04-14 Karl-Klaus Prof. Dr. Conzelmann Recombinant infectious non-segmented negative strand RNA virus
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
HUP0302278A3 (en) 1999-04-15 2011-01-28 Pro Virus Treatment of neoplasms with viruses
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
AU4971500A (en) 1999-05-05 2000-11-21 University Of Maryland Production of novel newcastle disease virus strains from cdnas and improved liveattenuated newcastle disease vaccines
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
DK1383795T3 (da) 2000-11-02 2007-05-29 Intervet Int Bv Rekombinant nucleoproteinmutant fra Newcastle disease-virus som markörvaccine
US20030044386A1 (en) 2001-07-11 2003-03-06 Barber Glen N. Recombinant VSV for the treatment of tumor cells
ATE307606T1 (de) 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
US20040072276A1 (en) 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
CA2529589A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
KR20070085314A (ko) 2004-11-12 2007-08-27 바이엘 쉐링 파마 악티엔게젤샤프트 재조합 뉴캐슬 질환 바이러스
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株

Also Published As

Publication number Publication date
EP2237790A1 (en) 2010-10-13
AR070272A1 (es) 2010-03-25
KR20100113096A (ko) 2010-10-20
CN102099045A (zh) 2011-06-15
CL2009000190A1 (es) 2010-07-19
BRPI0906354A2 (pt) 2019-12-17
US20100092430A1 (en) 2010-04-15
TW200936159A (en) 2009-09-01
EP2085092A1 (en) 2009-08-05
ZA201006151B (en) 2012-02-29
CO6290693A2 (es) 2011-06-20
ECSP10010375A (es) 2010-08-31
EA201001202A1 (ru) 2011-02-28
IL206382A0 (en) 2010-12-30
DOP2010000233A (es) 2010-08-15
CA2711571A1 (en) 2009-08-06
AU2009210301A1 (en) 2009-08-06
PE20091355A1 (es) 2009-10-04
MX2010008370A (es) 2010-08-23
JP2011510638A (ja) 2011-04-07
CR11616A (es) 2010-09-09
WO2009095167A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
PA8813901A1 (es) Paramixovirus oncolíticos atenuados que codifican citoquinas de aves
AR115692A2 (es) Método para la producción de promotores constitutivos de plantas, constructos y células transgénicas
ES2568803T3 (es) Reducción del contenido de ácidos grasos saturados en semillas de plantas
ES2192945B1 (es) Un metodo para interferir con la infeccion de virus en plantas.
UA109418C2 (uk) Конструйований білок з цинковими пальцями, направлений на гени рослин, залучені до біосинтезу жирних кислот
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
AR059257A1 (es) Genes para mejorar la eficiencia de la utilizacion de nitrogeno en los cultivos
AR084377A1 (es) Metodos y composiciones relacionados con enzimas de alcohol graso biosintetico
MY151062A (en) Pseudoinfectious flavivirus and uses thereof
IL189193A0 (en) Transplastomic plants expressing lumen-targeted protein
EA201492202A1 (ru) Способ экспрессии гетерологичных белков с использованием рекомбинантного вирусного вектора с минус-нитью рнк
AR059650A1 (es) Plantas que presentan aumento en el rendimiento y metodo para lograrlo
EA201390592A1 (ru) Аллели 1-d-дезоксиксилулозо-5-фосфат синтазы, ответственные за усиленный биосинтез терпенов
MX2021009554A (es) Produccion de virus en cultivos celulares.
WO2009099877A3 (en) Closterovirus vectors and methods
AR082510A1 (es) Metodo para aumentar la resistencia a infecciones fungicas en plantas transgenicas mediante el gen hcp-2
AR053279A1 (es) Regulacion post-transcripcional de la expresion genica
AR103794A1 (es) Producción de alquenos
AR100382A1 (es) Método para producir nailon
GB2458419A (en) Vector for expressing NC protein of HIV and method for producing NC protein using the same
AR095472A1 (es) Promotores constitutivos de soja
UY32488A (es) Lipasa cpo y derivados de la misma
AR069885A1 (es) Metodos para producir el virus de estomatitis vesicular (vsv) atenuado en un cultivo celular y para mejorar el empaque del vsv de propagacion defectuosa, composicion inmunogenica, celula aislada y secuencia de control transcripcional
AR090340A1 (es) Operaciones de cosecha mejoradas para proteinas recombinadas